TAOYUAN, June 25, 2025 /PRNewswire/ -- Plug and Play, the world's largest innovation platform, has officially opened its first office in Taoyuan City. This expansion...
MIAMI, June 12, 2025 /PRNewswire/ -- Blockticity, a blockchain and AI platform securing global trade documents, has launched a custom Avalanche Layer 1 network via...
Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.
New charitable foundation and hands-on robotics, software, and STEM lab to operate from Plug and Play Foundation's Innovation Lab, offering immersive learning and industry...
SUNNYVALE, Calif., June 9, 2025 /PRNewswire/ -- In a significant step forward for agricultural finance, American AgCredit (AAC), Farm Credit Services of America (FCSAmerica), Frontier...
TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que les conjugués anticorps-médicaments (ADC) (4174. TWO), et TegMine Therapeutics, Inc. (TegMine), une entreprise biopharmaceutique américaine spécialisée dans le développement d’anticorps de premier ordre ciblant les glycanes et glycoprotéines tumoraux, ont conclu un accord-cadre de services (MSA) portant sur les ADC.
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA).
SUNNYVALE, Calif., June 5, 2025 /PRNewswire/ -- Plug and Play, the world's largest innovation platform based in Silicon Valley, has announced a new collaboration with...